437 related articles for article (PubMed ID: 15357680)
41. STRO-1 confers myofibroblast transdifferentiation in fibroblasts derived from oral submucous fibrosis.
Yu CC; Liao YW; Yu CH; Chang YC
J Oral Pathol Med; 2018 Mar; 47(3):299-305. PubMed ID: 29210111
[TBL] [Abstract][Full Text] [Related]
42. miR-200b ameliorates myofibroblast transdifferentiation in precancerous oral submucous fibrosis through targeting ZEB2.
Liao YW; Yu CC; Hsieh PL; Chang YC
J Cell Mol Med; 2018 Sep; 22(9):4130-4138. PubMed ID: 29893466
[TBL] [Abstract][Full Text] [Related]
43. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline.
Jeng JH; Wang YJ; Chiang BL; Lee PH; Chan CP; Ho YS; Wang TM; Lee JJ; Hahn LJ; Chang MC
Carcinogenesis; 2003 Aug; 24(8):1301-15. PubMed ID: 12807728
[TBL] [Abstract][Full Text] [Related]
44. [Effect of arecoline on the differentiation of myofibroblasts of oral mucosa].
Li X; Ling TY; Gao YJ
Zhonghua Kou Qiang Yi Xue Za Zhi; 2007 Jul; 42(7):423-7. PubMed ID: 17961364
[TBL] [Abstract][Full Text] [Related]
45. An in-vitro comparison of human fibroblasts from normal and oral submucous fibrosis tissue.
Meghji S; Scutt A; Harvey W; Canniff JP
Arch Oral Biol; 1987; 32(3):213-5. PubMed ID: 3478024
[TBL] [Abstract][Full Text] [Related]
46. Oral precancerous disorders associated with areca quid chewing, smoking, and alcohol drinking in southern Taiwan.
Chung CH; Yang YH; Wang TY; Shieh TY; Warnakulasuriya S
J Oral Pathol Med; 2005 Sep; 34(8):460-6. PubMed ID: 16091112
[TBL] [Abstract][Full Text] [Related]
47. Synergistic effects of peroxynitrite on arecoline-induced cytotoxicity in human buccal mucosal fibroblasts.
Chang YC; Tai KW; Chou MY; Tseng TH
Toxicol Lett; 2000 Dec; 118(1-2):61-8. PubMed ID: 11137310
[TBL] [Abstract][Full Text] [Related]
48. The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut.
Canniff JP; Harvey W
Int J Oral Surg; 1981; 10(Suppl 1):163-7. PubMed ID: 6807873
[TBL] [Abstract][Full Text] [Related]
49. Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis.
Haque MF; Meghji S; Nazir R; Harris M
J Oral Pathol Med; 2001 Jan; 30(1):12-21. PubMed ID: 11140895
[TBL] [Abstract][Full Text] [Related]
50. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function.
Lin HJ; Lin JC
Oral Dis; 2007 Jul; 13(4):407-13. PubMed ID: 17577328
[TBL] [Abstract][Full Text] [Related]
51. Tanshinone Suppresses Arecoline-Induced Epithelial-Mesenchymal Transition in Oral Submucous Fibrosis by Epigenetically Reactivating the p53 Pathway.
Zheng L; Guan ZJ; Pan WT; Du TF; Zhai YJ; Guo J
Oncol Res; 2018 Apr; 26(3):483-494. PubMed ID: 28550687
[TBL] [Abstract][Full Text] [Related]
52. Genotoxic and non-genotoxic effects of betel quid ingredients on oral mucosal fibroblasts in vitro.
Jeng JH; Kuo ML; Hahn LJ; Kuo MY
J Dent Res; 1994 May; 73(5):1043-9. PubMed ID: 8006230
[TBL] [Abstract][Full Text] [Related]
53. Visceral organ involvement is infrequent in oral submucous fibrosis (OSF).
Rajendra R; George B; Sivakaran S; Narendranathan N
Indian J Dent Res; 2001; 12(1):7-20. PubMed ID: 11441804
[TBL] [Abstract][Full Text] [Related]
54. Deficiencies in collagen phagocytosis by human fibroblasts in vitro: a mechanism for fibrosis?
McCulloch CA; Knowles GC
J Cell Physiol; 1993 Jun; 155(3):461-71. PubMed ID: 8491787
[TBL] [Abstract][Full Text] [Related]
55. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids.
Harvey W; Scutt A; Meghji S; Canniff JP
Arch Oral Biol; 1986; 31(1):45-9. PubMed ID: 3458437
[TBL] [Abstract][Full Text] [Related]
56. Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis.
Dai JP; Chen J; Bei YF; Han BX; Wang S
J Oral Pathol Med; 2009 Mar; 38(3):276-81. PubMed ID: 19267840
[TBL] [Abstract][Full Text] [Related]
57. Cytotoxic and cytostatic effects of arecoline on oral mucosal fibroblasts.
Tsai CL; Kuo MY; Hahn LJ; Kuo YS; Yang PJ; Jeng JH
Proc Natl Sci Counc Repub China B; 1997 Oct; 21(4):161-7. PubMed ID: 9369025
[TBL] [Abstract][Full Text] [Related]
58. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis.
Yang SF; Hsieh YS; Tsai CH; Chou MY; Chang YC
Oral Oncol; 2003 Jun; 39(4):367-72. PubMed ID: 12676256
[TBL] [Abstract][Full Text] [Related]
59. Comparing dose-response measurements of oral habits on oral leukoplakia and oral submucous fibrosis from a community screening program.
Yang YH; Ho PS; Lu HM; Huang IY; Chen CH
J Oral Pathol Med; 2010 Apr; 39(4):306-12. PubMed ID: 20149061
[TBL] [Abstract][Full Text] [Related]
60. Cytological study of copper in oral submucous fibrosis.
Rooban T; Saraswathi TR; George A; Joshua E; Ranganathan K
Indian J Dent Res; 2004; 15(4):129-32. PubMed ID: 16035640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
